longfellow... you may be right, but we'll have to see what the results bear out. Certainly Matt Henkel, who was in that trial, didn't fare particularly well. He began treatment somewhere around Feb 10, 2021 and died a little more than 3 months later, around May 19, 2021.
This trial will also demonstrate how a recurrent GBM patient might do having received just DCVax-L alone... and using their recurrent tumor to make the vaccine. So that's another important reason for having moved forward with this combo trial.
News 
Market Data 
Discover 
